As a fitness professional, I frequently encounter questions about the use of Ozempic (Semaglutide: GLP-1 Receptor Agonists) for weight loss. My professional responsibility guides me to advise clients to consult with their healthcare provider, particularly when I'm aware that they don't have Type 2 Diabetes. I immediately think to myself about the potential long-term effects of using these drugs solely for weight loss purposes.
The increasing popularity of these drugs presents a complex challenge for employers. As healthcare costs rise, driven in part by such prescriptions, companies face escalating insurance premiums and growing employee out-of-pocket expenses. This financial strain might compel employers to reconsider the range of health plans they can feasibly offer.
This issue is multi-faceted. One aspect to consider is the role of endorsements. In an era where social media offers unprecedented access to celebrity health and fitness regimes, there's a lack of transparency about the rigorous monitoring and understanding of risks involved in these regimens. Celebrities may openly share their use of peptides, supplements, nutrition, and exercise routines, but often without disclosing the comprehensive medical oversight they receive.
Furthermore, the availability of Ozempic in settings like medical spas, which traditionally focus on services like facials, lasers, and botox, marks a significant shift in how these drugs are being marketed and used – extending even into weight loss services.
The case study mentioned below highlights what can happen when someone discontinues long-term Ozempic use without adopting healthier lifestyle habits. The key question then becomes: What lessons or sustainable health behaviors are being missed in this process? Medical intervention is critical for those in need. As fitness and health professionals, it's imperative to consider these broader implications, advocating for a holistic approach to health and wellness that extends beyond quick fixes.
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.Â